Gentamicin for Junctional Epidermolysis Bullosa

Plain-language summary

This study evaluates the drug Gentamicin Sulfate in patients with junctional epidermolysis bullosa, an inherited skin disease. It is enrolling patients who have nonsense mutations in the LAMB3 gene. The study is being conducted in Phase 1/Phase 2 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE1/PHASE2

Status

Recruiting

Sponsor

University of Southern California

Intervention

Gentamicin Sulfate

Start date

6/1/2018

Estimated completion

8/31/2020

Countries

United States

Related genes

Locations

• Los Angeles, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1\. JEB patients with nonsense mutations in the LAMB3 gene in either one or two alleles.

Exclusion Criteria:

1. JEB patients who do not have nonsense mutations in the LAMB3 gene in either allele.
2. Pre-existing known auditory impairment.
3. Pre-existing known renal impairment.
4. Pre-existing known allergies to aminoglycosides or sulfate compounds.
5. Pregnancy.